Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia

BACKGROUND: Ezetimibe ameliorates serum low-density lipoprotein cholesterol (LDL-c) and it has been approved for the treatment of hypercholesterolemia. However, the effects of ezetimibe on specific biomarkers have not been fully clarified in obese Japanese patients. METHODS: A total of 101 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Hisashi, Nakano, Hitoshi, Yamamoto, Kiichiro, Nakata, Masashi, Bekki, Hisatoshi, Honma, Tomoki, Yoshiyama, Hideki, Nohara, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417195/
https://www.ncbi.nlm.nih.gov/pubmed/25575766
http://dx.doi.org/10.1186/1476-511X-14-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417195/
https://www.ncbi.nlm.nih.gov/pubmed/25575766
http://dx.doi.org/10.1186/1476-511X-14-1

Ejemplares similares